Whatever the reasons, AstraZeneca has emerged as the first IL-33 player to show consistent efficacy. Sanofi and Regeneron ...
Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...
GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.
March 27 () - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful reduction in ...
Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced ...
Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary ...
Positive high‑level results from the phase 3 OBERON and TITANIA trials indicate that tozorakimab achieved statistically significant and clinically meaningful reductions in the a ...
AstraZeneca’s tozorakimab meets primary endpoint in both OBERON and TITANIA phase III trials in patients with COPD: Cambridge, UK Saturday, March 28, 2026, 11:00 Hrs [IST] Posit ...
Russell Winwood's chronic obstructive pulmonary disease (COPD) diagnosis in 2011 was a brutal wake-up call. His second in less than a decade. The Brisbane native, who came to be known as the “COPD ...
Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD –– Results from Phase 3 study of ...
Drugmaker AstraZeneca said on Friday that its monoclonal antibody tozorakimab had met the primary endpoint in both of its ...
8d
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualized rate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results